SF Healthcare Week: Beam's CEO John Evans shares an update on based editing for alpha-1 antitrypsin deficiency, sickle cell disease, and more
BiotechTV - News
00:00
Platform potential and upcoming liver target
John explains platform reusability, customizable guides, regulator receptivity, and teases a new liver-mediated target.
Play episode from 08:18
Transcript
